Dare Bioscience, Inc. (DARE) Dividend History

Company News

• Daré Bioscience Posts Narrower Q2 Loss

  Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.

  The Motley Fool

  Featured Companies: OGN
• UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

  Daré Bioscience announced a webinar on August 6, 2025, introducing DARE to PLAY™, a novel sildenafil cream designed to improve female sexual arousal, targeting prescription availability in Q4 2025.

  GlobeNewswire Inc.

  Featured Companies: OGN
• Dare Bioscience regains Nasdaq compliance with bid price - Investing.com

  Dare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.

  Investing.com
• Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

  Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research
• HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To Know

  HC Wainwright & Co. has decided to maintain its Buy rating of Dare Bioscience (NASDAQ:DARE) and raise its price target from $6.00 to $7.00. Shares of Dare Bioscience are trading up 2.84% over the last 24 hours, at $0.96 per share. A move to $7.00 would account for a 631.99% increase from the current share price. About Dare Bioscience Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal ...Full story available on Benzinga.com

  Benzinga